Shoulder Innovations Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
32.5%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$68.4Mnext fiscal year
FY EPS (est.)
-$1.86next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Third Quarter 2026 Financial Results | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Net Revenue Quarterly16.7MTarget: 65000000 to 68000000
Implant Systems Sold Quarterly2.2K
Average Selling Price (ASP) of Implant Systems Quarterly7.7K
Gross Margin Quarterly77.7%
Core and Contender Surgeons Annually134.0
Watch Items
- Commercial Launch of InSet I-135RFX Humeral StemTrigger: Full commercial launch initiated on April 27, 2026Action: Monitor surgeon adoption rates, hospital system onboarding, and sequential volume growth in subsequent quarters.
- Strategic Partnership with Interventional Systems (INS) for Robotic PlatformTrigger: Development of shoulder-specific micro-robotic platform integrated with ProVoyance systemAction: Track milestone achievements, R&D spending levels, and regulatory submission timelines for the robotic platform.
- Operating Loss and Cash Burn RateTrigger: Q1 2026 operating loss of $9.0 million and cash balance of $108.5 millionAction: Evaluate SG&A leverage and cash runway to ensure the company has sufficient capital to reach profitability without dilutive financing.
Research as of 20 Jun 2026